S Duarte, BSc
Surveying Stigma: MAFLD’s Nomenclature from Patient and Provider Perspectives
Non-alcoholic fatty liver disease (NAFLD) is estimated to affect 38% of adults worldwide, a statistic which is expected to increase with the rise of type 2 diabetes and obesity.
Read MoreSurveying Stigma: MAFLD’s Nomenclature from Patient and Provider PerspectivesCardiovascular Disease in MASLD Patients: Mitigating Risks
The term metabolic dysfunction-associated steatotic liver disease (MASLD) has recently been proposed as an alternative to non-alcoholic fatty liver disease (NAFLD)’s exclusionary nomenclature.
Read MoreCardiovascular Disease in MASLD Patients: Mitigating RisksExploring the Promise of Pan-PPAR Agonism
Peroxisome proliferated-activated receptors (PPARs), including α, β/δ and γ isotypes, are a nuclear receptor family of lipid sensors activated by natural fatty acid derivatives and pharmacological agonists.
Read MoreExploring the Promise of Pan-PPAR AgonismMachine Learning Models for the Detection of (At-Risk) NASH: Unravelling the Potential
Despite its health complications and inherent intra- and inter-observer variability, liver biopsy remains the gold standard for the detection of non-alcoholic steatohepatitis (NASH).
Read MoreMachine Learning Models for the Detection of (At-Risk) NASH: Unravelling the PotentialDiscerning sex-related differences in NAFLD patients via metabolic profiling
Research into personalised medicine for non-alcoholic fatty liver disease (NAFLD) underscores the importance of acknowledging NAFLD patients’ unique clinical phenotypes when developing targeted pharmacotherapies.
Read MoreDiscerning sex-related differences in NAFLD patients via metabolic profilingDe Novo Steatosis Post-Liver Transplantation: Prevalence and Risk Factors
Non-hepatic metabolic conditions represent crucial drivers of post-liver transplant morbidity and mortality.
Read MoreDe Novo Steatosis Post-Liver Transplantation: Prevalence and Risk FactorsMultiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD), affects 30% of adults worldwide and up to 40% of those with type 1 diabetes mellitus (T1DM)
Read MoreMultiple Daily Injections Versus Continuous Subcutaneous Insulin Infusion: Differential MAFLD Risks in Patients With Type 1 Diabetes?Research Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient Care
Both non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), NAFLD’s inflammatory and progressive subtype, are the histologic manifestations of a heterogeneous disease intricately linked with metabolic disorders.
Read MoreResearch Priorities in NAFLD: Ensuring Personalised and Multidisciplinary Patient CareThe Long Road to NASH Therapeutics: Uncovering Valuable Insights
Recent research indicates that 30% of adults worldwide, 90% of those with obesity, and 70% with type 2 diabetes are affected by non-alcoholic fatty liver disease (NAFLD).
Read MoreThe Long Road to NASH Therapeutics: Uncovering Valuable InsightsLiver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?
Liver-related events contribute to a small proportion of mortality within the collective cohort of patients with non-alcoholic fatty liver disease (NAFLD).
Read MoreLiver Stiffness and All-Cause Mortality in NAFLD Patients: Is There an Independent Link?NAFLD and Pancreatic Steatosis: A Bidirectional Relationship?
Recent research supports the existence of a potential link between non-alcoholic fatty liver disease (NAFLD) and fatty pancreas.
Read MoreNAFLD and Pancreatic Steatosis: A Bidirectional Relationship?Managing Comorbidities Before and During NASH Trials: Recommendations From the Liver Forum
The coexistence of numerous and primarily metabolism-related comorbidities is a common characteristic of patients with non-alcoholic steatohepatitis (NASH).
Read MoreManaging Comorbidities Before and During NASH Trials: Recommendations From the Liver ForumDr. S. Duarte graduated in Nutrition from the Universidade Paulista in 2007, got a Master in Clinical Gastroenterology Program at the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO in 2015 and became Doctor of Science in Gastroenterology from the FACULDADE DE MEDICINA DA UNIVERSIDADE DE SÃO PAULO (2019) . He is currently a professor of undergraduate classes at Universidade Paulista. Has a background in nutrition, with a focus on gut microbiota assessment in Non-Alcoholic Fatty Liver Disease (NAFLD).
SUBSCRIBE & FOLLOW US
SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES